
The FDA set a June 25, 2027, target date to review Celcuity’s application for patients with PIK3CA-mutant breast cancer.
Celcuity said the FDA accepted its supplemental application for REVTORPYK to treat certain patients with PIK3CA-mutant breast cancer. The FDA set a June 25, 2027, goal date for its decision.
The application covers patients with hormone receptor-positive, HER2-negative locally advanced or metastatic disease whose cancer progressed during or after at least one line of endocrine therapy in the metastatic setting. It is based on data from the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial.
The FDA approved REVTORPYK in July 2026, in combination with fulvestrant, with or without palbociclib, for a similar patient group without a detected PIK3CA mutation.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.